» Articles » PMID: 29032510

Current Prognostic and Predictive Factors in Follicular Lymphoma

Overview
Journal Ann Hematol
Specialty Hematology
Date 2017 Oct 17
PMID 29032510
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day treatments, long remissions are often achieved both in the front-line and relapsed setting. However, a subset of patients has a more aggressive course and a worse outcome. Their identification is the main purpose of modern day prognostic tools. In this review, we attempt to summarize the evidence concerning prognostic and predictive factors in FL, including (1) pre-treatment factors, from baseline clinical characteristics and imaging tests to histological grade, the microenvironment and genomic abnormalities; (2) post-treatment factors, i.e., depth of response, measured both by imaging tests and minimal residual disease; (3) factors at relapse and duration of response; and (4) prognostic factors in histological transformation. We conclude that, despite the existence of numerous tools, the availability of some of them is still limited; they generally suffer from notable downsides, and most have unproven predictive value, thus having scarce bearing on the choice of regimen at present. However, with the technological and scientific developments of the last few years, the potential for these prognostic factors is promising, particularly in combination, which will probably, in time, help guide therapeutic decisions.

Citing Articles

Unraveling the complexity of follicular lymphoma: insights and innovations.

Li X, Li N, Liu Y, An L Am J Cancer Res. 2025; 14(12):5573-5597.

PMID: 39803651 PMC: 11711519. DOI: 10.62347/MFUG2190.


Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.

Rajamaki A, Sorigue M, Prusila R, Kuusisto M, Kuitunen H, Jantunen E Acta Oncol. 2024; 63:267-272.

PMID: 38709114 PMC: 11332539. DOI: 10.2340/1651-226X.2024.24377.


Gene 72 Arg/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia.

Ounalli A, Moumni I, Mechaal A, Chakroun A, Barmat M, Rhim R Front Oncol. 2023; 13:1272876.

PMID: 37909012 PMC: 10613635. DOI: 10.3389/fonc.2023.1272876.


Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.

Durot C, Durot E, Mule S, Morland D, Godard F, Quinquenel A Diagnostics (Basel). 2023; 13(13).

PMID: 37443630 PMC: 10340740. DOI: 10.3390/diagnostics13132237.


Small volume biopsy diagnostic yield at initial diagnosis versus recurrence/transformation of follicular lymphoma: A retrospective Cyto-Heme Interinstitutional Collaborative study.

Fitzpatrick M, Sundaram V, Ly A, Abramson J, Balassanian R, Cheung M Cancer Cytopathol. 2022; 131(5):279-288.

PMID: 36573933 PMC: 10557381. DOI: 10.1002/cncy.22676.